The user is concerned about patchy hair regrowth after 5.5 months of treatment. They are questioning if more hair growth can be expected in the upcoming months.
The user experienced hair regrowth after using oral minoxidil, topical minoxidil, dutasteride, multivitamins, and ketoconazole shampoo, with noticeable improvement in the hairline after 11 months. They reported a burning sensation on the scalp and questioned if single hair follicles could become multi-hair follicles.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
User with diffused thinning hair prefers receding temples, as hair transplant could fix it. Finasteride and minoxidil suggested to improve hair density.
A user is concerned about hair shedding despite noticeable regrowth after 7 months of using finasteride. The dermatologist confirmed positive results, but the user remains skeptical and confused.
A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.
A user shared an 8.5-month update on their hair transplant of 1064 grafts done by Dr. Kaan Pekiner in Ankara, Turkey, costing $3500. They are also using finasteride 2.25 mg weekly and have reduced shampoo use.
The post is about a user's hair transplant results after one week, with 4000 grafts implanted. The conversation includes discussions about the healing process, shedding phase, and the number of grafts used.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.
User shared before and after photos of hair regrowth using Dutasteride 5x a week for 19 months. They experienced significant improvement and thanked others for their support.
Hair loss discussion involves experimenting with Sulforaphane from broccoli sprouts and possibly procyanidin b2. People seek updates on progress and if it's worth adding to treatment stack like microneedling.
User noticed black dots along the hairline and temples, questioning if it's regrowth. They are using a regimen including Dutasteride, oral and topical Minoxidil, and a compounded topical treatment.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.
Peptides, specifically GHK-Cu, are being considered for hair growth benefits, such as increasing blood flow to the scalp and preventing hair follicle shrinkage. A user reported starting GHK-Cu after hearing it made a friend's hair thicker.
A 35-year-old shared a 7-day update on their hair transplant, which involved 3,153 grafts performed by Dr. Elif at HLC Ankara, costing 10,000 euros including accommodations. The user has been on finasteride for over 12 years and opted for a partial shave FUE to address hairline recession and temple peaks.
People are sharing their experiences with different dosages of dutasteride and finasteride for hair loss. Many report shedding initially but some see improvements over time, with some also using minoxidil.
OP experienced significant hair regrowth after recovering from iron deficiency anemia and starting minoxidil. They suspect anemia contributed more to their hair loss than androgenetic alopecia (AGA).
Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.
Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.
A product that makes hair look thicker and healthier without promoting regrowth. Discussions include treatments like minoxidil, finasteride, red light therapy, and a serum with caffeine and peptides, with mixed effectiveness opinions.
The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.